tiprankstipranks
Advertisement
Advertisement

RCKT Stock Latest News

Is RCKT a Buy, Before Earnings?
Pre-EarningsIs RCKT a Buy, Before Earnings?
41m ago
RCKT
Rocket Pharmaceuticals Retains Hold Rating as Early Danon Phase 2 Safety Data Ease Concerns but Regulatory Path Keeps Risk‑Reward Balanced
PremiumRatings
Rocket Pharmaceuticals Retains Hold Rating as Early Danon Phase 2 Safety Data Ease Concerns but Regulatory Path Keeps Risk‑Reward Balanced
4d ago
RCKT
Rocket Pharmaceuticals Reports Positive Danon Disease Safety Update
PremiumCompany Announcements
Rocket Pharmaceuticals Reports Positive Danon Disease Safety Update
5d ago
8K
RCKT
Rocket announces safety update from three patients treated with RP-A501
PremiumThe Fly
Rocket announces safety update from three patients treated with RP-A501
5d ago
RCKT
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
PremiumMarket News
RedHill (RDHL) Gains FDA Rare Pediatric Disease Designation, Opening Door to Potential Priority Review Voucher (PRV) Upside
2M ago
GILD
JAZZ
Rocket Pharmaceuticals Strengthens Cash Position via Voucher Sale
PremiumCompany AnnouncementsRocket Pharmaceuticals Strengthens Cash Position via Voucher Sale
2M ago
8K
RCKT
Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M
Premium
The Fly
Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M
2M ago
RCKT
Rocket Pharmaceuticals price target raised to $10 from $9 at BofA
Premium
The Fly
Rocket Pharmaceuticals price target raised to $10 from $9 at BofA
2M ago
RCKT
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals
PremiumCompany Announcements
Rocket Pharmaceuticals Shareholders Approve 2026 Governance Proposals
3M ago
8K
RCKT
Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
PremiumRatings
Balanced View on Rocket: Hold Rating Reaffirmed as Danon Trial Resumes Under Revised Protocol and Pipeline Progress Offsets Ongoing Safety and Execution Risks
3M ago
RCKT
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
PremiumRatings
Rocket Pharmaceuticals: Buy Rating Reaffirmed and $10 Price Target Maintained on Advancing Gene Therapy Pipeline and Extended Cash Runway
3M ago
RCKT
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
PremiumThe Fly
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
3M ago
RCKT
Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway
PremiumCompany AnnouncementsRocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway
3M ago
8K
RCKT
Rocket Pharmaceuticals announces $180M sale of priority review voucher
Premium
The Fly
Rocket Pharmaceuticals announces $180M sale of priority review voucher
3M ago
RCKT
Rocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar
Premium
Company Announcements
Rocket Pharma Advances Cardiac Gene Therapy Trial, Keeping RCKT on Investors’ Radar
4M ago
RCKT
Rocket Pharmaceuticals price target raised to $9 from $8 at BofA
PremiumThe Fly
Rocket Pharmaceuticals price target raised to $9 from $8 at BofA
4M ago
RCKT
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
PremiumRatings
Balancing Early Gene Therapy Validation Against Limited Near-Term Revenue and Pipeline Risk: Rationale for Maintaining a Hold on Rocket
4M ago
RCKT
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
PremiumThe Fly
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
4M ago
RCKT
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
PremiumThe Fly
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
4M ago
RCKT
Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush
PremiumThe FlyRocket Pharmaceuticals stock weakness unwarranted, says Wedbush
4M ago
RCKT
Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
Premium
Ratings
Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating
4M ago
RCKT
Rocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
Premium
Ratings
Rocket Pharmaceuticals: Kresladi Approval, Non‑Dilutive Capital, and Danon Pipeline Progress Underscore Buy Rating Despite Share Weakness
4M ago
RCKT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >